Our R&D pipeline reflects a commitment to driving change to defeat chronic metabolic and neurodegenerative conditions

In addition to our clinical-stage compounds, our scientists are working on novel and innovative treatments that serve as “balanced metabolic modulators,” purposely designed to restore the right balance for mitochondrial health and to address the unmet needs of people living with obesity and associated cardiometabolic conditions as well as neurodegeneration.

Product CandidatesDiscoveryNon-GLP ToxIND EnablingPhase 1

Alcoholic Hepatitis

HTD4010

Read Less

Quality Weight Modulation

HTF1037 (Mitochondria uncoupler)

Read Less
Mitochondria uncoupler plus
(multiple novel chemical matters)

Read Less

Neurodegenerative Diseases

HTF1057 (Mitochondria uncoupler)

Read Less
Mitochondria uncoupler plus
(novel chemical matter)

Read Less
Therapeutic AreaPhase
Alcoholic Hepatitis HTD4010Phase 1

Read Less
Therapeutic AreaPhase
Quality Weight Modulation HTF1037 (Mitochondria uncoupler)IND Enabling

Read Less
Quality Weight Modulation Mitochondria uncoupler plus
(multiple novel chemical matters)
Discovery

Read Less
Therapeutic AreaPhase
Neurodegenerative Diseases HTF1057 (Mitochondria uncoupler)Non-GLP Tox

Read Less
Neurodegenerative Diseases Mitochondria uncoupler plus
(novel chemical matter)
Discovery

Read Less

Updated October 2024

HTD4010 is an investigational product and a clinical-stage compound under development for acute inflammatory-related indications including alcoholic hepatitis. The compound is a peptide derived from the Reg3a protein with expected immunomodulatory, anti-inflammatory, and anti-apoptotic effects. HTD4010 has been evaluated in animal models of acute pancreatitis and acute liver failure, where protective effects were observed.

The benefits of weight loss are well understood. In obese patients, weight loss ameliorates the metabolic risk factors for diabetes, coronary artery disease, and obesity-associated cancers. However, these health benefits can be compromised by weight-associated loss of lean body mass, which could increase the risk of sarcopenia, decreased mobility, increased frailty and an overall reduction in quality of life.

Activating the metabolic process of mitochondrial uncoupling is expected to result in not only muscle sparing weight loss, but also enhancement of endurance through increasing type-I muscle percentage; reduction of liver and visceral fat; improved glycemic control, and reductions in oxidative stress and inflammation.

Neurodegenerative diseases present one of the most formidable therapeutic challenges of our time. Despite decades of dedicated research, effective treatments and preventive measures remain elusive. In the context of neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, Lou Gehrig’s diseases and multiple sclerosis, mitochondrial dysfunction is one of the key disease features.

Mitochondria uncouplers can help reduce oxidative stress and prevent calcium overload. This, in addition to other mechanisms that improve neuronal mitochondria health, may allow for more effective treatments in the future.

Collaboration and Partnerships

HighTide is dedicated to broadening our efforts to provide patients with access to innovative and transformative medicines through collaborations or partnerships. We seek out like-minded companies who are pioneering innovative treatments and interventions, leveraging cutting-edge research and technology to develop effective therapies. We have specific interests in exploring:

  • Additional indications for our lead clinical asset berberine ursodeoxycholate
  • Accelerating development of our discovery portfolio to address and manage obesity and neurodegenerative disease

Please contact our business development team at bd@hightidetx.com.